Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
May 06 2022 - 4:03PM
Edgar (US Regulatory)
As Filed Pursuant to Rule 424(b)(5)
Registration No. 333-258994
PROSPECTUS SUPPLEMENT
(To Prospectus dated August 30, 2021 and the Prospectus Supplement dated September 30, 2021)
ELOXX PHARMACEUTICALS,
INC.
Up to $12,996,794.66
of Common Stock
This Prospectus Supplement supplements
the prospectus supplement, dated September 30, 2021 (the “ATM Prospectus Supplement”), relating to the offer and sale of shares
of our common stock having an aggregate offering price of up to $50,000,000 pursuant to the terms of a sales agreement, or the Sales Agreement,
with SVB Securities LLC (“SVB Securities”). Through the date hereof, we have not sold any shares of our common stock through
SVB Securities under the Sales Agreement. This Prospectus Supplement should be read in conjunction with the ATM Prospectus Supplement,
and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained
in the ATM Prospectus Supplement. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection
with, the ATM Prospectus Supplement, and any future amendments or supplements thereto.
On March 30, 2022, the date we
filed our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, we became subject to the offering limits in General
Instruction I.B.6 of Form S-3. As of the date of this Prospectus Supplement, the aggregate market value of our common stock held by non-affiliates
pursuant to General Instruction I.B.6 of Form S-3 is $38,990,384, which was calculated based on 67,224,800 shares of our outstanding common
stock held by non-affiliates and a price of $0.58 per share, the closing price of our common stock on April 4, 2022, which is the highest
closing sale price of our common stock on the Nasdaq Global Market within the prior 60 days. As of the date of this Prospectus Supplement,
we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including,
the date of this Prospectus Supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public
primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12
calendar month period so long as our public float remains below $75.0 million.
We are filing this Prospectus
Supplement to amend the ATM Prospectus Supplement to reflect the limitations on the maximum amount of shares that we are eligible to sell
under General Instruction I.B.6. As a result of these limitations, we may currently only offer and sell shares of our common stock having
an aggregate offering price of up to $12,996,794.66 pursuant to the Sales Agreement. However, in the event that our public float increases
or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to one-third of our public float, in each
case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Sales Agreement. In the event that our public float
increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3.
Sales of common stock under this
Prospectus Supplement, if any, will be made by means of ordinary brokers’ transactions through the facilities of the Nasdaq Global
Market, any other national securities exchange or facility thereof, a trading facility of a national securities association or an alternate
trading system, to or through a market maker or directly on or through an electronic communication network or any similar market venue,
at market prices, in block transactions or as otherwise agreed between us and the sales agent. Our common stock trades on the Nasdaq Global
Market under the symbol “ELOX.” On May 5, 2022, the last reported sale price of our common stock on the Nasdaq Global Market
was $0.33 per share.
INVESTING IN OUR SECURITIES
INVOLVES RISKS. SEE THE “RISK FACTORS” ON PAGE S-8 OF THE ATM PROSPECTUS SUPPLEMENT AND IN THE DOCUMENTS INCORPORATED
BY REFERENCE IN THE REGISTRATION STATEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.
Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or
accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
SVB
Securities
The date of this prospectus supplement is
May 6, 2022.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jul 2023 to Jul 2024